Prime Medicine, Inc.
PRME
$1.60
-$0.06-3.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.98M | 800.00K | 591.00K | 591.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.98M | 800.00K | 591.00K | 591.00K | -- |
| Cost of Revenue | 155.29M | 162.64M | 163.27M | 154.80M | 147.91M |
| Gross Profit | -152.31M | -161.84M | -162.68M | -154.21M | -147.91M |
| SG&A Expenses | 50.16M | 50.94M | 47.34M | 45.39M | 43.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 205.45M | 213.59M | 210.61M | 200.19M | 191.29M |
| Operating Income | -202.47M | -212.79M | -210.02M | -199.60M | -191.29M |
| Income Before Tax | -195.88M | -219.25M | -217.55M | -204.44M | -198.41M |
| Income Tax Expenses | 0.00 | 0.00 | -108.00K | 57.00K | -279.00K |
| Earnings from Continuing Operations | -195.88 | -219.25 | -217.44 | -204.50 | -198.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -195.88M | -219.25M | -217.44M | -204.50M | -198.13M |
| EBIT | -202.47M | -212.79M | -210.02M | -199.60M | -191.29M |
| EBITDA | -196.34M | -207.13M | -204.68M | -194.68M | -186.64M |
| EPS Basic | -1.66 | -2.05 | -2.16 | -2.17 | -2.17 |
| Normalized Basic EPS | -1.05 | -1.21 | -1.28 | -1.30 | -1.29 |
| EPS Diluted | -1.66 | -2.05 | -2.16 | -2.17 | -2.17 |
| Normalized Diluted EPS | -1.05 | -1.21 | -1.28 | -1.30 | -1.29 |
| Average Basic Shares Outstanding | 474.34M | 435.89M | 407.97M | 379.25M | 363.85M |
| Average Diluted Shares Outstanding | 474.34M | 435.89M | 407.97M | 379.25M | 363.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |